RESULTS
This study enrolled 333 patients with a median age of 59 (19-91) years,
with a proportion of patients aged less than 50 years being 23.4%
(n=78); 50-50 years being 28.5% (n=95); 60-69 years being 27.3%
(n=91); 70-79 years being 15.3% (n=51); and >80 years
being 5.4% (n=18). In total, 58.6% of patients (n=195) were male and
41.4% were female (n=138).
According to the total number of comorbidities enrolled in Charlson,
11.7% (n=39) of patients had no comorbidities, 30.9% (n=103) of
patients had one comorbidity, 20.1% (n=67) of patients had two
comorbidities, and 37.2% (n=124) of patients had more than three
comorbidities. Diabetes mellitus (33.6%, n=112) and cerebrovascular
disease (25.2%, n=84) were the two most common comorbidities reported
by patients in this study. Patients were hospitalized for an average of
8 (1-37) days throughout treatment. The median age of COVID-19 patients
who died was 67 (26-91) years, whereas the median age of COVID-19
patients who survived was 57 (19-86) years.
The unadjusted analysis revealed that the following variables contribute
to a greater likelihood of death in patients with COVID-19: older
patient age, greater comorbidities, longer hospital stay, and several
types of comorbidities in the patient. In multivariate analysis, these
variables were significantly related to short-term mortality in COVID-19
patients: older age (odds ratio [OR] per year 1.64; 95% confidence
interval [CI] 1.23-2.19; p 0.001), myocardial infarction (OR 3.57 ;
95% CI 1.49-8.56; p: 0.004), diabetes mellitus (OR 2.41; 95 CI
1.17-4.97; p: 0.017), renal disease (OR 5.18 ; 95% CI 2.07-12.97; p
<0.001), and longer duration of stay (OR 1.20; 95% CI
1.08-1.32; p <0.001).